[HTML][HTML] Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
Z Lu, H Chen, S Li, J Gong, J Li, J Zou… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Despite the great achievements made in immune-checkpoint-blockade (ICB) in
cancer therapy, there are no effective predictive biomarkers in gastrointestinal (GI) cancer …
cancer therapy, there are no effective predictive biomarkers in gastrointestinal (GI) cancer …
Collateral lethality: a new therapeutic strategy in oncology
FL Muller, EA Aquilanti, RA DePinho - Trends in cancer, 2015 - cell.com
Genomic deletion of tumor suppressor genes (TSGs) is a rite of passage for virtually all
human cancers. The synthetic lethal paradigm has provided a framework for the …
human cancers. The synthetic lethal paradigm has provided a framework for the …
[HTML][HTML] The use of biomarkers in prostate cancer screening and treatment
Prostate cancer screening and diagnosis has been guided by prostate-specific antigen
levels for the past 25 years, but with the most recent US Preventive Services Task Force …
levels for the past 25 years, but with the most recent US Preventive Services Task Force …
Genomic control of metastasis
SA Patel, P Rodrigues, L Wesolowski… - British Journal of …, 2021 - nature.com
Metastasis remains the leading cause of cancer-associated mortality, and a detailed
understanding of the metastatic process could suggest new therapeutic avenues. However …
understanding of the metastatic process could suggest new therapeutic avenues. However …
[HTML][HTML] Elucidating prostate cancer behaviour during treatment via low-pass whole-genome sequencing of circulating tumour DNA
Background Better blood tests to elucidate the behaviour of metastatic castration-resistant
prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell …
prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell …
Age influences on the molecular presentation of tumours
Cancer is often called a disease of aging. There are numerous ways in which cancer
epidemiology and behaviour change with the age of the patient. The molecular bases for …
epidemiology and behaviour change with the age of the patient. The molecular bases for …
Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine
A Nurminen, S Jaatinen, S Taavitsainen, G Högnäs… - Genome medicine, 2023 - Springer
Abstract Background Prostate cancer (PrCa) genomic heterogeneity causes resistance to
therapies such as androgen deprivation. Such heterogeneity can be deciphered in the …
therapies such as androgen deprivation. Such heterogeneity can be deciphered in the …
Low CD38 identifies progenitor-like inflammation-associated luminal cells that can initiate human prostate cancer and predict poor outcome
Inflammation is a risk factor for prostate cancer, but the mechanisms by which inflammation
increases that risk are poorly understood. Here, we demonstrate that low expression of …
increases that risk are poorly understood. Here, we demonstrate that low expression of …
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Purpose: Leiomyosarcoma (LMS) is an aggressive sarcoma for which standard
chemotherapies achieve response rates under 30%. There are no effective targeted …
chemotherapies achieve response rates under 30%. There are no effective targeted …
The influence of BRCA2 mutation on localized prostate cancer
A key challenge in the management of localized prostate cancer is the identification of men
with a high likelihood of progression to an advanced, incurable stage. Patients who harbour …
with a high likelihood of progression to an advanced, incurable stage. Patients who harbour …